Skip to main content
. 2023 Aug 10;12(8):1702–1716. doi: 10.21037/tlcr-22-736

Figure 1.

Figure 1

Kaplan-Meier plots of investigator-assessed PFS in the exploratory liquid biopsy addendum by (A) dichotomized baseline circulating EGFR‑activating mutation (ex19del or ex21.L858R) allele count (low vs. high; subgroups based on the count of EGFR‑activating mutation alleles at baseline above or below the median count of 102) and (B) Cycle 4 circulating EGFR‑activating mutation (ex19del or ex21.L858R) alleles (undetectable vs. detectable). EGFR, epidermal growth factor receptor; ERL, erlotinib; ex19del, exon 19 deletion; ex21.L858R, exon 21 L858R point mutation; PFS, progression-free survival; PL, placebo; RAM, ramucirumab.